The trading price of Atyr Pharma Inc (NASDAQ:ATYR) closed lower on Friday, December 27, and closing at $3.74, -0.80% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $3.6429 and $3.98. In examining the 52-week price action we see that the stock hit a 52-week high of $3.80 and a 52-week low of $1.38. Over the past month, the stock has gained 13.68% in value.
Atyr Pharma Inc, whose market valuation is $311.44 million at the time of this writing, is expected to release its quarterly earnings report in January. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest ATYR has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
A quick review shows that ATYR’s price is currently 12.45% off the SMA20 and 15.77% off the SMA50. The RSI metric on the 14-day chart is currently showing 67.12, and weekly volatility stands at 8.16%. When measured over the past 30 days, the indicator reaches 7.44%. Atyr Pharma Inc (NASDAQ:ATYR)’s beta value is currently sitting at 1.09, while the Average True Range indicator is currently displaying 0.25.
To see how Atyr Pharma Inc stock has been performing in comparison to its peers in the industry, here are the numbers: ATYR stock’s performance was -0.80% in the latest trading, and 154.42% in the past year.
An evaluation of the daily trading volume of Atyr Pharma Inc (NASDAQ:ATYR) indicates that the 3-month average is 1.03 million. However, this figure has increased over the past 10 days to an average of 0.96.
Currently, records show that 83.94 million of the company’s shares remain outstanding. The insiders hold 2.36% of outstanding shares, whereas institutions hold 63.01%. The stats also highlight that short interest as of 2024-12-13, stood at 2.92 million shares, resulting in a short ratio of 3.71 at that time. From this, we can conclude that short interest is 458.00 of the company’s total outstanding shares. It is noteworthy that short shares in December were up slightly from the previous month’s figure, which was 2.11 million. However, since the stock’s price has seen 165.25% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
